Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 20Unknown 3Terminated 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma 3Hodgkin Disease 3Glioblastoma 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Gliosarcoma 2Central Nervous System Neoplasms 2Burkitt Lymphoma 2Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Leukemia, Large Granular Lymphocytic 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Enteropathy-Associated T-Cell Lymphoma 1Breast Neoplasms 1

Interventions

Radiosurgery 10Temozolomide 6Magnetic Resonance Spectroscopy 6pembrolizumab 3Trastuzumab 3Radiation 3fluciclovine F-18 2cabazitaxel 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Imaging 2Erlotinib Hydrochloride 2Carboplatin 2Bevacizumab 2Aminolevulinic Acid 2tucatinib 1thymoglobulin 1tepotinib 1temsirolimus 1sodium thiosulfate 1ribociclib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1neratinib 1lenvatinib 1irinotecan sucrosofate 1gancotamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Brain Neoplasms × Carmustine × Clear all
NCT02348255 2018-01-09

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

University of California, Davis

Phase 2 Withdrawn
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡